Connection
David Camidge to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications David Camidge has written about Clinical Trials, Phase II as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.383 |
|
|
|
-
Phillips WJ, Watson AS, Camidge DR. The Use of Investigator-Assigned Subjective or Judgmental Efficacy and Toxicity Reporting in Early Phase Clinical Trials of Lung Cancer Treatments. J Thorac Oncol. 2025 May; 20(5):589-596.
Score: 0.233
-
Soria JC, Ho SN, Varella-Garcia M, Iafrate AJ, Solomon BJ, Shaw AT, Blackhall F, Mok TS, Wu YL, Pestova K, Wilner KD, Polli A, Paolini J, Lanzalone S, Green S, Camidge DR. Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. Ann Oncol. 2018 09 01; 29(9):1964-1971.
Score: 0.151